Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence of human papillomavirus in squamous cell carcinomas of the soft palate

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Incidental lymphopenia and mortality: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: The JAK2 V617F mutation is highly recurrent in many of the myeloproliferative neoplasms, a molecular variant that can be easily detected using sensitive and minimally invasive techniques. Given the ease of JAK2 V617F testing, this test may be improperly requested for the purposes of patient 'screening' and to optimise laboratory resource utilisation, it behooves clinicians and laboratorians to perform JAK2 V617F testing only when most appropriate.

METHODS: To assist with the screening of patients being considered for JAK2 V617F testing, we developed a clinical decision rule, "JAK2-tree", which can be easily applied to basic CBC parameters (haemoglobin, platelet and white blood cell counts).

RESULTS: We tested JAK2-tree on two independent datasets, one an unselected population-based sample (the Copenhagen General Population Study) and the other an historical clinical laboratory referral set, with sensitivities for JAK2 V617F detection of 91% and 94%, respectively. As applied to the historical laboratory referral dataset, moreover, the JAK2-tree algorithm would have reduced JAK2 V617F testing volume over the period of evaluation by 15%.

CONCLUSIONS: Our work supports a simple decision-tree-based screening approach to optimize the selection of patients most appropriate for JAK2 V617F testing.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Pathology
Vol/bind72
Udgave nummer2
Sider (fra-til)172-176
Antal sider5
ISSN0021-9746
DOI
StatusUdgivet - feb. 2019

ID: 56639076